Substance P vs Humanin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →Side-by-Side Comparison
| Aspect | Substance P | Humanin |
|---|---|---|
| Mechanism | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. |
| Typical Dosage | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. |
| Administration | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. |
| Side Effects | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. |
| Best For |
What They Have in Common
Both Substance P and Humanin are commonly used for: